Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7853147 | 1.00 | DPP4 (0.41) | DPP4NTMT1GRB2F2PLG | |
| SCHEMBL9577364 | 1.00 | DPP4 (0.41) | DPP4NTMT1GRB2F2PLG | |
| SCHEMBL31124688 | 0.96 | OPRM1 (0.41) | NTMT1GRB2F2OPRM1OPRK1 | |
| SCHEMBL31437198 | 0.93 | NTMT1 (0.41) | DPP4NTMT1F2OPRM1OPRK1 | |
| SCHEMBL29569634 | 0.92 | NTMT1 (0.47) | NTMT1GRB2F2OPRM1OPRK1 | |
| SCHEMBL29886815 | 0.91 | DPP4 (0.42) | DPP4NTMT1GRB2F2PLG | |
| SCHEMBL30452201 | 0.91 | NRP1 (0.43) | GRB2OPRM1OPRK1 | |
| SCHEMBL29556306 | 0.91 | BDKRB2 (0.39) | DPP4OPRM1 | |
| SCHEMBL5863304 | 0.91 | EPHA2 (0.41) | DPP4NTMT1OPRM1OPRK1 | |
| SCHEMBL31124690 | 0.91 | OPRM1 (0.43) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613743-B2 | Process for the production and purification of the collagenase enzyme from Vibrio alginolyticus | FIDIA FARMACEUTICI S.P.A. (IT) | 2023-03-28 | — | — | US | disclosed |
| US-20200354707-A1 | PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2020-11-12 | — | — | US | disclosed |
| US-10774319-B2 | Process for the production and purification of the collagenase enzyme from vibrio alginolyticus | FIDIA FARMACEUTICI S.P.A. (IT) | 2020-09-15 | — | — | US | disclosed |
| CN-111424025-A | Novel method for producing and purifying collagenase from Vibrio alginolyticus (Vibrio algirlyticus) | 菲迪亚制药股份公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-104508127-B | Novel method for producing and purifying collagenase from Vibrio alginolyticus (Vibrio algirlyticus) | 菲迪亚制药股份公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20170314005-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2017-11-02 | — | — | US | disclosed |
| US-9738883-B2 | Process for the production and purification of the collagenase enzyme from vibrio alginolyticus | FIDIA FARMACEUTICALS S.P.A. (IT) | 2017-08-22 | — | — | US | disclosed |
| EP-2839000-B1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-20150056179-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| EP-2839000-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | Fidia Farmaceutici S.p.A. (IT) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156525-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056179-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | MMP8, MMP1, MMP2 | DPP4 555/4885NTMT1 2466/4885GRB2 4765/4885 |
| US-10774319-B2 | Process for the production and purification of the collagenase enzyme from vibrio alginolyticus | MMP8, MMP1, MMP2 | DPP4 567/4885NTMT1 2635/4885GRB2 4740/4885 |
| US-20170314005-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | MMP8, MMP1, MMP2 | DPP4 519/4885NTMT1 2550/4885GRB2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.